AF Screening Publications

To download the EndNote file please click: AF Screen Bibliography Refs

  1. Chan, N.Y., Systematic Screening for Atrial Fibrillation in the Community: Evidence and Obstacles. Arrhythm Electrophysiol Rev, 2018. 7(1): p. 39-42.
  2. Engdahl, J., et al., A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation. Europace, 2018.
  3. Jacobs, M.S., et al., Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace, 2018. 20(1): p. 12-18.
  4. Jacobs, M.S., M. van Hulst, and R.G. Tieleman, Letter responding to Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societad Latinoamericana de Estimulation Cardiaca y Electrofisiologia (SOLAECE). Europace, 2018.
  5. Linker, D.T., T.B. Murphy, and A.H. Mokdad, Selective screening for atrial fibrillation using multivariable risk models. Heart, 2018.
  6. Mairesse, G.H. and G. Boriani, Letter responding to Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societad Latinoamericana de Estimulation Cardiaca y Electrofisiologia (SOLAECE)-Authors’ Reply. Europace, 2018.
  7. Sabater-Hernandez, D., et al., A stakeholder co-design approach for developing a community pharmacy service to enhance screening and management of atrial fibrillation. BMC Health Serv Res, 2018. 18(1): p. 145.
  8. Singh, N., et al., Clinical Implications of Technological Advances in Screening for Atrial Fibrillation. Prog Cardiovasc Dis, 2018. 60(4-5): p. 550-559.
  9. Tavernier, R., et al., Screening for atrial fibrillation in hospitalised geriatric patients. Heart, 2018. 104(7): p. 588-593.
  10. Veale, E.L., et al., Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol. BMJ Open, 2018. 8(3): p. e021121.
  11. Yan, B.P., et al., Contact-Free Screening of Atrial Fibrillation by a Smartphone Using Facial Pulsatile Photoplethysmographic Signals. J Am Heart Assoc, 2018. 7(8).
  12. Zink, M.D., et al., Opportunities and challenges of large-scale screening for atrial fibrillation. Herzschrittmacherther Elektrophysiol, 2018.
  13. Aronsson, M., et al., Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis. Europace, 2017. 19(10): p. 1650-1656.
  14. Berge, T., et al., Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke: data from the Akershus Cardiac Examination 1950 study. Europace, 2017.
  15. Camm, A.J., et al., Atrial high-rate episodes and stroke prevention. Europace, 2017. 19(2): p. 169-179.
  16. Chan, N.Y. and C.C. Choy, Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart, 2017. 103(1): p. 24-31.
  17. Chan, P.H., et al., Head-to-Head Comparison of the AliveCor Heart Monitor and Microlife WatchBP Office AFIB for Atrial Fibrillation Screening in a Primary Care Setting. Circulation, 2017. 135(1): p. 110-112.
  18. Chan, P.H., et al., Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. BMJ Open, 2017. 7(6): p. e013685.
  19. Chen, Y.H., et al., Atrial Fibrillation Screening in Nonmetropolitan Areas Using a Telehealth Surveillance System With an Embedded Cloud-Computing Algorithm: Prospective Pilot Study. JMIR Mhealth Uhealth, 2017. 5(9): p. e135.
  20. Conti, S., et al., Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. J Atr Fibrillation, 2017. 9(5): p. 1551.
  21. Desteghe, L., et al., Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace, 2017. 19(1): p. 29-39.
  22. Engdahl, J., et al., Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design. Europace, 2017. 19(2): p. 297-302.
  23. Fay, M.R., D.A. Fitzmaurice, and B. Freedman, Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice. Eur J Gen Pract, 2017. 23(1): p. 246-253.
  24. Freedman, B., et al., Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol, 2017. 14(12): p. 701-714.
  25. Freedman, B., et al., Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation, 2017. 135(19): p. 1851-1867.
  26. Genta, P.R., L.F. Drager, and G. Lorenzi Filho, Screening for Obstructive Sleep Apnea in Patients with Atrial Fibrillation. Sleep Med Clin, 2017. 12(1): p. 99-105.
  27. Guenancia, C., et al., [Screening and clinical implications of silent atrial fibrillation]. Rev Med Interne, 2017.
  28. Halcox, J.P.J., et al., Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation, 2017. 136(19): p. 1784-1794.
  29. Hald, J., et al., Opportunistic screening for atrial fibrillation in a real-life setting in general practice in Denmark-The Atrial Fibrillation Found On Routine Detection (AFFORD) non-interventional study. PLoS One, 2017. 12(11): p. e0188086.
  30. Hess, P.L., et al., The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. JAMA Cardiol, 2017. 2(3): p. 324-331.
  31. Kirchhof, P., Blank, B., Calvert, M., Camm, A. J., Chlouverakis, G., Diener, H. C., Goette, A, Huening, A., Lip, G Y H., Simantirakis, E. and Vardas, P, Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH – AFNET 6) trial. American Heart Journal, 2017. in press.
  32. Lopes, R.D., Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal, 2017. in press.
  33. Lown, M., et al., Screening for Atrial Fibrillation using Economical and accurate TechnologY (SAFETY)-a pilot study. BMJ Open, 2017. 7(1): p. e013535.
  34. Lubitz, S.A., et al., Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study. Stroke, 2017. 48(2): p. 490-492.
  35. Mairesse, G.H., et al., Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace, 2017. 19(10): p. 1589-1623.
  36. Modesti, P.A., et al., The involvement of pharmacies in the screening of undiagnosed atrial fibrillation. Intern Emerg Med, 2017. 12(8): p. 1081-1086.
  37. Nasir, J.M., et al., PREdicting Determinants of Atrial Fibrillation for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study. Heart Rhythm, 2017.
  38. Neubeck, L., et al., To Screen or Not to Screen? Examining the Arguments Against Screening for Atrial Fibrillation. Heart Lung Circ, 2017. 26(9): p. 880-886.
  39. Quinn, G.R., et al., Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. Circulation, 2017. 135(3): p. 208-219.
  40. Reiffel, J.A., et al., High Incidence Of Previously Unknown (“Silent”) Atrial Fibrillation In Patients At High Risk For Atrial Fibrillation And Stroke: Primary Results From The REVEAL AF Study. http://www.abstractsonline.com/pp8/#!/4227/presentation/12996; Assessed on 17th May 2017, 2017.
  41. Soni, A., et al., Study protocol for Smartphone Monitoring for Atrial fibrillation in Real-Time in India (SMART-India): a community-based screening and referral programme. BMJ Open, 2017. 7(12): p. e017668.
  42. Svennberg, E., et al., N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation. Heart, 2017. 103(16): p. 1271-1277.
  43. Svennberg, E., et al., Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation. Europace, 2017. 19(9): p. 1449-1453.
  44. Tarride, J.E., et al., Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ Open, 2017. 5(3): p. E653-e661.
  45. Van Gelder, I.C., et al., Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J, 2017. 38(17): p. 1339-1344.
  46. Wachter, R., et al., Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol, 2017. 16(4): p. 282-290.
  47. Welton, N.J., et al., Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. Health Technol Assess, 2017. 21(29): p. 1-236.
  48. Wiesel, J. and T.J. Salomone, Screening for Atrial Fibrillation in Patients >/=65 Years Using an Automatic Blood Pressure Monitor in a Skilled Nursing Facility. Am J Cardiol, 2017. 120(8): p. 1322-1324.
  49. National-Institute-for-Health-and-Care-Excellence. Medical technology guidance: Watch BP Home A for diagnosing and monitoring hypertension and detecting atrial fibrillation. 2016.
  50. Boriani, G. and D. Pettorelli, Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol, 2016. 83: p. 26-35.
  51. Brachmann, J., et al., Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol, 2016. 9(1): p. e003333.
  52. Camm, A.J., et al., XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J, 2016. 37(14): p. 1145-53.
  53. Carmo, J., et al., Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost, 2016. 116(4): p. 754-63.
  54. Chan, P.H., et al., Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. J Am Heart Assoc, 2016. 5(7): p. e003428.
  55. Eckman, M.H., et al., Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. Am Heart J, 2016. 176: p. 17-27.
  56. Engdahl, J., et al., Geographic and socio-demographic differences in uptake of population-based screening for atrial fibrillation: The STROKESTOP I study. Int J Cardiol, 2016. 222: p. 430-5.
  57. Fabritz, L., et al., Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol, 2016. 13(4): p. 230-7.
  58. Freedman, B., Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That? J Am Heart Assoc, 2016. 5(7).
  59. Freedman, B., et al., Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. JAMA Cardiol, 2016. 1(3): p. 366-8.
  60. Freedman, B., T.S. Potpara, and G.Y. Lip, Stroke prevention in atrial fibrillation. Lancet, 2016. 388(10046): p. 806-17.
  61. Ganesan, A.N., et al., The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J, 2016. 37(20): p. 1591-602.
  62. Goette, A., et al., EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace, 2016. 18(10): p. 1455-1490.
  63. Gwynne, K., et al., Opportunistic screening to detect atrial fibrillation in Aboriginal adults in Australia. BMJ Open, 2016. 6(11): p. e013576.
  64. Haeusler, K.G., et al., Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. Am Heart J, 2016. 172: p. 19-25.
  65. Healey, J., et al., Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients With Cardiovascular Risk Factors: ASSERT II. Circulation, 2016. 134: p. e714.
  66. Hobbs, F.R., et al., European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol, 2016. 23(5): p. 460-73.
  67. Hsu, J.C., et al., Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. JAMA Cardiol, 2016. 1(1): p. 55-62.
  68. Jacobs, M.S., et al., Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace, 2016.
  69. Kaasenbrood, F., et al., Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace, 2016. 18(10): p. 1514-1520.
  70. Kamel, H., et al., Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke, 2016. 47(3): p. 895-900.
  71. Katritsis, D.G.C., et al., European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J, 2016.
  72. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016. 37(38): p. 2893-2962.
  73. Lowres, N., et al., Self-monitoring for atrial fibrillation recurrence in the discharge period post-cardiac surgery using an iPhone electrocardiogram. Eur J Cardiothorac Surg, 2016. 50(1): p. 44-51.
  74. Lowres, N., L. Neubeck, and S.B. Freedman, Can screening for atrial fibrillation be implemented at scale? Europace, 2016. 18(10): p. 1449-1451.
  75. Lowres, N., et al., Choice of Health Options In prevention of Cardiovascular Events for people with Atrial Fibrillation (CHOICE-AF): A pilot study. Eur J Cardiovasc Nurs, 2016. 15(1): p. 39-46.
  76. Martinez, C., et al., Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost, 2016. 115(1): p. 31-9.
  77. McManus, D.D., et al., PULSESMART: Pulse-Based Arrhythmia Discrimination Using a Novel Smartphone Application. J Cardiovasc Electrophysiol, 2016. 27: p. 51-57.
  78. Mittal, S., et al., Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm, 2016. 13(8): p. 1624-30.
  79. Moran, P.S., et al., Systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev, 2016. 6: p. Cd009586.
  80. Nolker, G., et al., Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol, 2016. 27(12): p. 1403-1410.
  81. Omboni, S. and W.J. Verberk, Opportunistic screening of atrial fibrillation by automatic blood pressure measurement in the community. BMJ Open, 2016. 6(4): p. e010745.
  82. Orchard, J., et al., Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. European Journal of Preventive Cardiology, 2016. 23(2): p. suppl 13-20.
  83. Orchard, J., et al., Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. Eur J Prev Cardiol, 2016. 23(2 suppl): p. 13-20.
  84. Orchard, J., et al., Feasibility of screening for atrial fibrillation in primary care: Just a heartbeat away? Eur J Prev Cardiol, 2016. 23(16): p. 1783-1784.
  85. Perera, K.S., et al., Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry. Stroke, 2016. 47(9): p. 2197-202.
  86. Phrommintikul, A., et al., Prevalence of atrial fibrillation in Thai elderly. Journal of Geriatric Cardiology : JGC, 2016. 13(3): p. 270-273.
  87. Poli, S., et al., Insertable cardiac monitors after cryptogenic stroke–a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol, 2016. 23(2): p. 375-81.
  88. Proietti, M., et al., A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace, 2016: p. euw069.
  89. Proietti, M., et al., A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace, 2016. 18(12): p. 1779-1786.
  90. Sandhu, R.K., et al., High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart, 2016. 3(2): p. e000515.
  91. Siontis, K., B. Gersh, and J.e.a. Killian, Typical, atypical and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm, 2016. 0: p. 1-7.
  92. Smyth, B., et al., Opportunistic screening for atrial fibrillation in a rural area. QJM, 2016.
  93. Soni, A., et al., High Burden of Unrecognized Atrial Fibrillation in Rural India: An Innovative Community-Based Cross-Sectional Screening Program. JMIR Public Health Surveill, 2016. 2(2): p. e159.
  94. Steinhubl, S.R., et al., Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial. Am Heart J, 2016. 175: p. 77-85.
  95. Swiryn, S., et al., Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. Circulation, 2016. 134(16): p. 1130-1140.
  96. Taggar, J.S., et al., Screening for Atrial Fibrillation – A Cross-Sectional Survey of Healthcare Professionals in Primary Care. PLOS ONE, 2016. 11(4): p. e0152086.
  97. Thijs, V.N., et al., Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology, 2016. 86(3): p. 261-9.
  98. Tiwari, S., et al., CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromso Study. Open Heart, 2016. 3(2): p. e000439.
  99. Wachter, R., et al., Finding atrial fibrillation in stroke – randomised evaluation of enhanced and prolonged Holter-ECG, in Late breaking Clinical Trial International Stroke Conference 2016: Los Angeles.
  100. Walkey, A.J., et al., Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study. Chest, 2016. 149(1): p. 74-83.
  101. Yan, B., et al., Medical outpatient clinics an ideal setting for atrial fibrillation screening using a handheld single-lead ECG with automated diagnosis. Eur Heart J, 2016. 37(Abstract supplement): p. 888.
  102. Yong, J.H., et al., Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. Stroke, 2016. 47(9): p. 2380-5.
  103. Aronsson, M., et al., Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace, 2015. 17(7): p. 1023-9.
  104. Ben Freedman, S. and N. Lowres, Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. Jama, 2015. 314(18): p. 1911-2.
  105. Benito, L., et al., EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. Europace, 2015. 17(11): p. 1688-93.
  106. Boriani, G., et al., Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med, 2015. 128(5): p. 509-18 e2.
  107. Boriani, G. and L. Padeletti, Management of atrial fibrillation in bradyarrhythmias. Nat Rev Cardiol, 2015. 12(6): p. 337-49.
  108. Boriani, G., et al., Asymptomatic lone atrial fibrillation – how can we detect the arrhythmia? Curr Pharm Des, 2015. 21(5): p. 659-66.
  109. Bury, G., et al., Screening for atrial fibrillation in general practice: a national, cross-sectional study of an innovative technology. Int J Cardiol, 2015. 178: p. 247-52.
  110. Chei, C.L., et al., Prevalence and Risk Factors of Atrial Fibrillation in Chinese Elderly: Results from the Chinese Longitudinal Healthy Longevity Survey. Chin Med J (Engl), 2015. 128(18): p. 2426-32.
  111. Fauchier, L., et al., Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke, 2015. 46(9): p. 2432-7.
  112. Favilla, C.G., et al., Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke, 2015. 46(5): p. 1210-5.
  113. Filion, K.B., et al., High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J, 2015. 169(1): p. 31-8 e3.
  114. Freedman, B. and N. Lowres, Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. JAMA, 2015. 314(18): p. 1911-2.
  115. Freedman, S.B., et al., “Off the pulse” about incidental atrial fibrillation. Lancet, 2015. 386(10001): p. 1339-1340.
  116. Frontera, A., et al., Demographic and Clinical Characteristics to Predict Paroxysmal Atrial Fibrillation: Insights from an Implantable Loop Recorder Population. Pacing Clin Electrophysiol, 2015. 38(10): p. 1217-22.
  117. Gandolfo, C., et al., Validation of a simple method for atrial fibrillation screening in patients with stroke. Neurol Sci, 2015. 36(9): p. 1675-8.
  118. Guo, Y., et al., Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest, 2015. 147(1): p. 109-19.
  119. Health Information and Quality Authority. Health technology assessment (HTA) of a national screening programme for atrial fibrillation in primary care. 2015 [cited 2016 24 May]; Available from: https://www.hiqa.ie/publications/health-technology-assessment-hta-national-screening-programme-atrial-fibrillation-prima.
  120. Kamel, H., et al., Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol, 2015. 78(5): p. 670-8.
  121. Katzenellenbogen, J.M., et al., Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review. BMC Cardiovasc Disord, 2015. 15: p. 87.
  122. Lane, D.A., et al., Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace, 2015. 17(12): p. 1747-69.
  123. Larsen, B.S., et al., Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol, 2015. 66(3): p. 232-41.
  124. Li, L.-H., et al., The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study. BMC Cardiovascular Disorders, 2015. 15: p. 31.
  125. Lowres, N., et al., Identifying postoperative atrial fibrillation in cardiac surgical patients posthospital discharge, using iPhone ECG: a study protocol. BMJ Open, 2015. 5(1): p. e006849.
  126. Lowres, N., et al., Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm, 2015. 12(6): p. 350-60.
  127. Lubitz, S.A., et al., Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation, 2015. 131(19): p. 1648-55.
  128. Martin, D.T., et al., Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J, 2015. 36(26): p. 1660-8.
  129. Neubeck, L., et al., The mobile revolution–using smartphone apps to prevent cardiovascular disease. Nat Rev Cardiol, 2015. 12(6): p. 350-60.
  130. Phan, K., et al., New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J Cardiothorac Surg, 2015. 48(6): p. 817-24.
  131. Potter, B.J. and J. Le Lorier, Taking the pulse of atrial fibrillation. Lancet, 2015. 386(9989): p. 113-5.
  132. Shore, S., et al., Site-level variation in and practices associated with dabigatran adherence. JAMA, 2015. 313(14): p. 1443-50.
  133. Slotwiner, D., et al., HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm, 2015. 12(7): p. e69-100.
  134. Sposato, L.A., et al., Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol, 2015. 14(4): p. 377-87.
  135. Steinberg, B.A., et al., Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J, 2015. 36(5): p. 288-96.
  136. Svennberg, E., et al., Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation, 2015. 131(25): p. 2176-84.
  137. Tiwari, S., et al., Association between diastolic dysfunction and future atrial fibrillation in the Tromso Study from 1994 to 2010. Heart, 2015. 101(16): p. 1302-8.
  138. Tsuyuki, R.T., et al., Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation, 2015. 132(2): p. 93-100.
  139. Turakhia, M.P., et al., Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. Am J Cardiol, 2015. 116(5): p. 733-9.
  140. Turakhia, M.P., et al., Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol, 2015. 38(5): p. 285-92.
  141. Turakhia, M.P., et al., Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol, 2015. 8(5): p. 1040-7.
  142. Uittenbogaart, S.B., et al., Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. Trials, 2015. 16: p. 478.
  143. Vanassche, T., et al., Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J, 2015. 36(5): p. 281-7a.
  144. Walkey, A.J., D.K. Hogarth, and G.Y. Lip, Optimizing atrial fibrillation management: from ICU and beyond. Chest, 2015. 148(4): p. 859-64.
  145. Witt, C.T., et al., Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm, 2015. 12(12): p. 2368-75.
  146. Yaghi, S., et al., Left atrial enlargement and stroke recurrence: the northern Manhattan stroke study. Stroke, 2015. 46(6): p. 1488-93.
  147. Al-Khatib, S.M., et al., Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med, 2014. 160(11): p. 760-73.
  148. Bidar, E., et al., A prospective randomized controlled trial on the incidence and predictors of late-phase postoperative atrial fibrillation up to 30 days and the preventive value of biatrial pacing. Heart Rhythm, 2014. 11(7): p. 1156-62.
  149. Boriani, G., et al., Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J, 2014. 35(8): p. 508-16.
  150. Brambatti, M., et al., Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation, 2014. 129(21): p. 2094-9.
  151. Christensen, L.M., et al., Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. Eur J Neurol, 2014. 21(6): p. 884-9.
  152. Chugh, S.S., et al., Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation, 2014. 129(8): p. 837-47.
  153. Davy, J., et al., The French screening campaign of Atrial Fibrillation (PROFIL FA®) in general practice : Assessment of predictive criteria for atrial fibrillation (AF). ESC 2014 Barcelona. Eur Heart J, 2014. 35(abstract suppl): p. abstract 82393.
  154. Friberg, L., et al., High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke, 2014. 45(9): p. 2599-605.
  155. Gialdini, G., et al., Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA, 2014. 312(6): p. 616-22.
  156. Gladstone, D.J., et al., Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med, 2014. 370(26): p. 2467-77.
  157. Gonzalez, M., et al., Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers. Heart Rhythm, 2014. 11(12): p. 2214-21.
  158. Hart, R.G., et al., Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol, 2014. 13(4): p. 429-38.
  159. Hendrikx, T., et al., Intermittent short ECG recording is more effective than 24-hour Holter ECG in detection of arrhythmias. BMC Cardiovascular Disorders, 2014. 14(1): p. 41.
  160. January, C.T., et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 2014. 64(21): p. e1-76.
  161. Kasemsap, N., et al., Clinical Outcome in Atrial Fibrillation with Ischemic Stroke in Thai Patients. J Thai Stroke Soc 2014. 13: p. 48.
  162. Kearley, K., et al., Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open, 2014. 4(5): p. e004565.
  163. Kishore, A., et al., Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke, 2014. 45(2): p. 520-6.
  164. Lee, S.H., et al., New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J, 2014. 167(4): p. 593-600 e1.
  165. Lowres, N., et al., Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost, 2014. 111(6): p. 1167-76.
  166. Martinez, C., A. Katholing, and S.B. Freedman, Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thrombosis & Haemostasis, 2014. 112(2): p. 276-86.
  167. National-Institute-for-Health-and-Care-Excellence., Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180.) 2014. http://guidance.nice.org.uk/CG180. 2014: p. http://guidance.nice.org.uk/CG180.
  168. Orchard, J., et al., iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician, 2014. 43(5): p. 315-9.
  169. Rienstra, M., et al., Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. American Heart Journal, 2014. 167(1): p. 109-115.e2.
  170. Ruff, C.T., et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014. 383(9921): p. 955-62.
  171. Sanna, T., et al., Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med, 2014. 370(26): p. 2478-86.
  172. Schnabel, R.B., et al., Multiple biomarkers and atrial fibrillation in the general population. PLoS ONE [Electronic Resource], 2014. 9(11): p. e112486.
  173. Sinner, M.F., et al., B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014. 16(10): p. 1426-33.
  174. Sutamnartpong, P., et al., Atrial fibrillation and paroxysmal atrial fibrillation detection in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis, 2014. 23(5): p. 1138-41.
  175. Tieleman, R.G., et al., Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace, 2014. 16(9): p. 1291-5.
  176. Vaes, B., et al., The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care. BMC Family Practice, 2014. 15: p. 113.
  177. Verma, A., et al., 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol, 2014. 30(10): p. 1114-30.
  178. Virtanen, R., et al., Self-detection of atrial fibrillation in an aged population: the LietoAF Study. Eur J Prev Cardiol, 2014. 21(11): p. 1437-42.
  179. Walkey, A.J., E.J. Benjamin, and S.A. Lubitz, New-Onset Atrial Fibrillation During Hospitalization. Journal of the American College of Cardiology, 2014. 64(22): p. 2432-2433.
  180. Wiesel, J., B. Arbesfeld, and D. Schechter, Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol, 2014. 114(7): p. 1046-8.
  181. Willits, I., et al., WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: a NICE Medical Technology Guidance. Appl Health Econ Health Policy, 2014. 12(3): p. 255-65.
  182. Wong, C.X., et al., Atrial fibrillation in Indigenous and non-Indigenous Australians: a cross-sectional study. BMJ Open, 2014. 4(10): p. e006242.
  183. Arts, D.L., et al., Improving stroke prevention in patients with atrial fibrillation. Trials, 2013. 14: p. 193.
  184. Bjorck, S., et al., Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke, 2013. 44(11): p. 3103-8.
  185. Cotter, P.E., et al., Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology, 2013. 80(17): p. 1546-50.
  186. Deif, B., N. Lowres, and S.B. Freedman, Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol, 2013. 164(3): p. 371-2.
  187. Engdahl, J., et al., Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation, 2013. 127(8): p. 930-7.
  188. Ermini, G., A. Filippi, and M. Salera, Switching from traditional to automatic sphygmomanometer increases opportunistic detection of atrial fibrillation in hypertensive patients. BJMP, 2013. 6: p. a616.
  189. Etgen, T., et al., Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. Stroke, 2013. 44(7): p. 2007-9.
  190. Folsom, A.R., et al., Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke, 2013. 44(4): p. 961-7.
  191. Frewen, J., et al., Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM, 2013. 106(5): p. 415-24.
  192. Friberg, L. and L. Bergfeldt, Atrial fibrillation prevalence revisited. J Intern Med, 2013. 274(5): p. 461-8.
  193. Grond, M., et al., Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke, 2013. 44(12): p. 3357-64.
  194. Healey, J.S., et al., Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol, 2013. 29(2): p. 224-8.
  195. Higgins, P., et al., Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke, 2013. 44(9): p. 2525-31.
  196. Hohnloser, S.H., et al., The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. Eur Heart J, 2013. 34(35): p. 2752-9.
  197. Jedsadayanmata, A., Patterns and adherence to guidelines of antithrombotic therapy in Thai patients with nonvalvular atrial fibrillation. J Med Assoc Thai, 2013. 96(1): p. 91-8.
  198. Kamel, H., et al., Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke. Stroke, 2013. 44(2): p. 528-30.
  199. Kottkamp, H., Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J, 2013. 34(35): p. 2731-8.
  200. Lau, J., et al., Performance of an Automated iPhone ECG Algorithm to Diagnose Atrial Fibrillation in a Community AF Screening Program (SEARCH-AF). Heart, Lung and Circulation, 2013. 22, Supplement 1: p. S205.
  201. Lau, J.K., et al., iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol, 2013. 165(1): p. 193-4.
  202. Li, Y., et al., Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci, 2013. 26(9): p. 709-16.
  203. Lowres, N., et al., Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost, 2013. 110(2): p. 213-22.
  204. Marijon, E., et al., Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation, 2013. 128(20): p. 2192-201.
  205. McManus, D.D., et al., A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm, 2013. 10(3): p. 315-9.
  206. Miller, D.J., et al., Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. J Neurol Sci, 2013. 324(1-2): p. 57-61.
  207. Norberg, J., et al., Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clinical Epidemiology, 2013. 5: p. 475-481.
  208. Pilote, L., et al., Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol, 2013. 29(10): p. 1241-8.
  209. Potpara, T.S., et al., A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol, 2013. 168(5): p. 4744-9.
  210. Rhys, G.C., M.F. Azhar, and A. Foster, Screening for atrial fibrillation in patients aged 65 years or over attending annual flu vaccination clinics at a single general practice. Qual Prim Care, 2013. 21(2): p. 131-40.
  211. Ritter, M.A., et al., Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke, 2013. 44(5): p. 1449-52.
  212. Rojo-Martinez, E., et al., [High performance of an implantable Holter monitor in the detection of concealed paroxysmal atrial fibrillation in patients with cryptogenic stroke and a suspected embolic mechanism]. Rev Neurol, 2013. 57(6): p. 251-7.
  213. Rosenberg, M.A., et al., Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol, 2013. 36(3): p. 328-33.
  214. Thacker, E.L., et al., Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology, 2013. 81(2): p. 119-25.
  215. Zoni-Berisso, M., et al., Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol, 2013. 111(5): p. 705-11.
  216. Bhave, P.D., et al., Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J, 2012. 164(6): p. 918-24.
  217. Boriani, G., et al., Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. Circ Cardiovasc Qual Outcomes, 2012. 5(2): p. 182-8.
  218. Camm, A.J., et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace, 2012. 14(10): p. 1385-413.
  219. Claes, N., et al., Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol, 2012. 67(3): p. 273-8.
  220. Doliwa Sobocinski, P., et al., Improved screening for silent atrial fibrillation after ischaemic stroke. Europace, 2012. 14(8): p. 1112-6.
  221. Flint, A.C., et al., Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke, 2012. 43(10): p. 2788-90.
  222. Haeusler, K.G., P. Kirchhof, and M. Endres, Left atrial catheter ablation and ischemic stroke. Stroke, 2012. 43(1): p. 265-70.
  223. Healey, J.S., et al., Subclinical atrial fibrillation and the risk of stroke. N Engl J Med, 2012. 366(2): p. 120-9.
  224. Kaufman, E.S., et al., Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm, 2012. 9(8): p. 1241-6.
  225. Lowres, N., et al., Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged >=65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open, 2012. 2(3).
  226. Lowres, N., et al., Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. Eur J Prev Cardiol, 2012. 19(5): p. 1091-100.
  227. Marazzi, G., et al., Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients.[Erratum appears in Adv Ther. 2014 Dec;31(12):1317]. Advances in Therapy, 2012. 29(1): p. 64-70.
  228. Ntaios, G., et al., Prevalence of atrial fibrillation in Greece: the Arcadia Rural Study on Atrial Fibrillation. Acta Cardiologica, 2012. 67(1): p. 65-9.
  229. Schnabel, R.B., et al., Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int, 2012. 109(16): p. 293-9.
  230. Shanmugam, N., et al., Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace, 2012. 14(2): p. 230-7.
  231. Ziegler, P.D., et al., Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol, 2012. 110(9): p. 1309-14.
  232. Ambrosetti, M., et al., Late postoperative atrial fibrillation after cardiac surgery: a national survey within the cardiac rehabilitation setting. J Cardiovasc Med (Hagerstown), 2011. 12(6): p. 390-5.
  233. Bhatt, A., et al., Predictors of occult paroxysmal atrial fibrillation in cryptogenic strokes detected by long-term noninvasive cardiac monitoring. Stroke Res Treat, 2011. 2011: p. 172074.
  234. Boriani, G., et al., Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke, 2011. 42(6): p. 1768-70.
  235. Charlemagne, A., et al., Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis, 2011. 104(2): p. 115-24.
  236. Charrois, T.L., et al., Improving hypertension management through pharmacist prescribing; the rural alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. Implementation Science : IS, 2011. 6: p. 94-94.
  237. Daoud, E.G., et al., Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm, 2011. 8(9): p. 1416-23.
  238. Evans, C.D., et al., Diabetes and cardiovascular disease interventions by community pharmacists: a systematic review. Ann Pharmacother, 2011. 45(5): p. 615-28.
  239. Kaw, R., et al., Short- and long-term mortality associated with new-onset atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis. J Thorac Cardiovasc Surg, 2011. 141(5): p. 1305-12.
  240. Lewis, M., et al., Screening for atrial fibrillation: sensitivity and specificity of a new methodology. British Journal of General Practice, 2011. 61(582): p. 38-9.
  241. Lobban, T.C. and A.J. Camm, Patient associations as stakeholders: a valuable partner for facilitating access to therapy. Europace, 2011. 13 Suppl 2: p. ii21-4.
  242. Long, M.J., et al., Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol, 2011. 148(1): p. 48-52.
  243. Sandhu, R.K., et al., Risk stratification schemes, anticoagulation use and outcomes: the risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart, 2011. 97(24): p. 2046-50.
  244. Sandhu, R.K., et al., The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. Am Heart J, 2011. 161(5): p. 986-992 e1.
  245. Santschi, V., et al., Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med, 2011. 171(16): p. 1441-53.
  246. Schotten, U., et al., Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev, 2011. 91(1): p. 265-325.
  247. Tsang, T.S., et al., Silent atrial fibrillation in olmsted county: A community-based study. Canadian Journal of Cardiology, 2011. 27(5): p. S122.
  248. Walkey, A.J., et al., Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA, 2011. 306(20): p. 2248-54.
  249. Camm, A.J., et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010. 31(19): p. 2369-429.
  250. Chien, K.L., et al., Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol, 2010. 139(2): p. 173-80.
  251. Dion, F., et al., Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study. J Interv Card Electrophysiol, 2010. 28(2): p. 101-7.
  252. El-Chami, M.F., et al., New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol, 2010. 55(13): p. 1370-6.
  253. European Heart Rhythm, A., et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 2010. 12(10): p. 1360-420.
  254. Filardo, G., et al., New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery. Ann Thorac Surg, 2010. 90(2): p. 474-9.
  255. Gaillard, N., et al., Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients. Neurology, 2010. 74(21): p. 1666-70.
  256. Hannon, N., et al., Stroke associated with atrial fibrillation–incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis, 2010. 29(1): p. 43-9.
  257. Matiello, M., et al., Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010. 12(8): p. 1084-9.
  258. Schnabel, R.B., et al., Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation, 2010. 121(2): p. 200-7.
  259. Ziegler, P.D., et al., Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke, 2010. 41(2): p. 256-60.
  260. Botto, G.L., et al., Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol, 2009. 20(3): p. 241-8.
  261. Doliwa, P.S., V. Frykman, and M. Rosenqvist, Short-term ECG for out of hospital detection of silent atrial fibrillation episodes. Scand Cardiovasc J, 2009. 43(3): p. 163-8.
  262. Elijovich, L., et al., Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis, 2009. 18(3): p. 185-9.
  263. Gladstone, D.J., et al., Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009. 40(1): p. 235-40.
  264. Glotzer, T.V., et al., The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol, 2009. 2(5): p. 474-80.
  265. Quirino, G., et al., Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol, 2009. 32(1): p. 91-8.
  266. Thygesen, S.K., et al., Atrial fibrillation in patients with ischemic stroke: A population-based study. Clin Epidemiol, 2009. 1: p. 55-65.
  267. Watson, T., E. Shantsila, and G.Y. Lip, Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet, 2009. 373(9658): p. 155-66.
  268. Das, R.R., et al., Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke, 2008. 39(11): p. 2929-35.
  269. Mittal, S., et al., Frequency, duration, and predictors of newly-diagnosed atrial fibrillation following dual-chamber pacemaker implantation in patients without a previous history of atrial fibrillation. Am J Cardiol, 2008. 102(4): p. 450-3.
  270. Tayal, A.H., et al., Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology, 2008. 71(21): p. 1696-701.
  271. Tveit, A., et al., Atrial fibrillation and antithrombotic therapy in a 75-year-old population. Cardiology, 2008. 109(4): p. 258-62.
  272. Yap, K.B., T.P. Ng, and H.Y. Ong, Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. Journal of Electrocardiology, 2008. 41(2): p. 94-8.
  273. Zhou, Z. and D. Hu, An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol, 2008. 18(5): p. 209-16.
  274. Arya, A., et al., Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol, 2007. 30(4): p. 458-62.
  275. Fitzmaurice, D.A., et al., Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ, 2007. 335(7616): p. 383.
  276. Hart, R.G., L.A. Pearce, and M.I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007. 146(12): p. 857-67.
  277. Nieuwlaat, R., et al., Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J, 2007. 153(6): p. 1006-12.
  278. Orlov, M.V., et al., Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol, 2007. 30(3): p. 404-11.
  279. Cheung, J.W., et al., Newly detected atrial fibrillation following dual chamber pacemaker implantation. J Cardiovasc Electrophysiol, 2006. 17(12): p. 1323-8.
  280. Cooke, G., J. Doust, and S. Sanders, Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract, 2006. 55(2): p. 130-4.
  281. Heeringa, J., et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J, 2006. 27(8): p. 949-53.
  282. Capucci, A., et al., Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol, 2005. 46(10): p. 1913-20.
  283. Hindricks, G., et al., Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation, 2005. 112(3): p. 307-13.
  284. Hobbs, F.D., et al., A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess, 2005. 9(40): p. iii-iv, ix-x, 1-74.
  285. Sherman, D.G., et al., Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med, 2005. 165(10): p. 1185-91.
  286. Tse, H.F. and C.P. Lau, Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. Heart, 2005. 91(3): p. 362-4.
  287. Humphries, K.H., et al., Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol, 2004. 20(9): p. 869-76.
  288. Israel, C.W., et al., Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol, 2004. 43(1): p. 47-52.
  289. Maeda, K., T. Shimbo, and T. Fukui, Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. J Med Screen, 2004. 11(2): p. 97-102.
  290. Glotzer, T.V., et al., Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation, 2003. 107(12): p. 1614-9.
  291. Gillis, A.M. and M. Morck, Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol, 2002. 13(6): p. 542-7.
  292. Cioffi, G., et al., Characterization of post-discharge atrial fibrillation following open-heart surgery in uncomplicated patients referred to an early rehabilitation program. Ital Heart J, 2001. 2(7): p. 519-28.
  293. Defaye, P., F. Dournaux, and E. Mouton, Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol, 1998. 21(1 Pt 2): p. 250-5.
  294. Jorgensen, H.S., et al., Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke, 1996. 27(10): p. 1765-9.
  295. Page, R.L., et al., Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation, 1994. 89(1): p. 224-7.
  296. Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. 22(8): p. 983-8.
  297. Wolf, P.A., et al., Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke, 1983. 14(5): p. 664-7.
  298. Ostrander, L.D., Jr., et al., ELECTROCARDIOGRAPHIC FINDINGS AMONG THE ADULT POPULATION OF A TOTAL NATURAL COMMUNITY, TECUMSEH, MICHIGAN. Circulation, 1965. 31: p. 888-98.
  299. Apiyasawat, S., et al., CHA<sub>2</sub>DS<sub>2</sub>-VASc scores predict mortality after hospitalization for atrial fibrillation. International Journal of Cardiology. 185: p. 293-296.
  300. Sun, G.-Z., et al., Prevalence of atrial fibrillation and its risk factors in rural China: A cross-sectional study. International Journal of Cardiology. 182: p. 13-17.